West Pharmaceutical Services stock
Price history
+58.02% over the period1 year: from $262.41 (November 17, 2025) to $414.66 (November 17, 2026), +58.02%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $414.66 |
| October 30, 2026 | $412.62 |
| September 30, 2026 | $370.76 |
| August 31, 2026 | $341.11 |
| July 31, 2026 | $340.96 |
| June 30, 2026 | $359.00 |
| May 29, 2026 | $322.81 |
| April 30, 2026 | $297.59 |
| March 31, 2026 | $250.64 |
| February 27, 2026 | $254.34 |
| January 30, 2026 | $231.12 |
| December 31, 2025 | $275.14 |
| November 28, 2025 | $277.25 |
| November 17, 2025 | $262.41 |
At a glance
The company
Design, manufacture and sell containment and delivery systems for injectable drugs and healthcare products globally
Latest results
Quarter to September 30, 2026 · EPS $2.66 (estimate $2.20)
TickerLandia's take on West Pharmaceutical Services
- Pricier than usual relative to earnings: P/E on the latest fiscal year 61 vs a median of 46 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 47 vs 34 (+37%) in a group of 9.
- Strong point: Market momentum (94/100 in its group). Weak point: Dividend (37/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.51% from the 52-week high
Analysts · 16 analysts
Average target$471.00+13.74% vs. price
Buy 15 · Hold 0 · Sell 1
TickerLandia Fingerprint: West Pharmaceutical Services
Compared with similar companies: very strong momentum and very high financial strength.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh79
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 46.7 62 Forward P/E 40.1 83 EV/EBITDA 30.0 80 Price/book 9.79 90 Price/sales 8.54 81 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 22.9% 72 Gross margin 37.6% 22 Net margin 18.8% 78 ROE 21.2% 78 ROA 11.9% 81 Earnings stabilityaverage51
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.4% 40 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage52
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +2.12% 22 Revenue growth (year over year) +8.70% 66 Earnings growth (year over year) +57.30% 69 Financial strengthvery high87
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 1,277.4 98 Debt/equitycounts in reverse: lower means more financial strength 0.11 80 Current ratio 2.82 84 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.57 86 Dividendlow37
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 94 Dividend yield 0.2% 7 Payout ratio 10.3% 10 Market momentumvery strong94
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +23.11% 94 Relative strength (6 months) +35.14% 90 1-year return +59.86% 93 Distance from 200-day average +29.62% 97 Risklow29
How much the price swings.
Metric Value Position in group Volatility (60 days) 22.8% 18 Beta (1 year) 0.64 48 Maximum drawdown (12 months) 18.8% 21
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
West Pharmaceutical Services is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), West Pharmaceutical Services's P/E today is 61.1, above the median of its last 10 fiscal years (45.8; between 30.4 and 62.0 from 2016 to 2025). West Pharmaceutical Services's P/E (trailing 12 months): 46.9, +37% against the median of a group of 9 similar companies (34.3).
Compared with 9 similar companies
| Metric | West Pharmaceutical Services | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 46.9 | High | |
| Forward P/E | 40.2 | High | |
| Operating margin | 22.9% | High | |
| ROE | 21.2% | High | |
| Debt/equity | 0.11 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: West Pharmaceutical Services. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$874.5M
Latest quarter · Q3 2026
Net income
$214M
Latest quarter · Q3 2026
Quarterly net margin
24.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $29.1B
- P/E
- 46.9
- EPS
- $8.91
- Volume
- 525.77K
- Daily trading
- €284.48M
- Dividend yield
- 0.22%
- Last ex-dividend on November 10, 2026
How West Pharmaceutical Services is changing
All resultsRevenue grew 7.4% a year on average over the last 5 years
Operating margin fell from 25.4% to 19.0%
Free cash flow equal to 73% of net income
Returns
West Pharmaceutical Services returns with dividends
$1,000 invested in West Pharmaceutical Services 5 years ago, on November 17, 2021, would be worth $945 today with dividends reinvested: −5.49% in total, −1.12% per year. On price alone it would be $933 (−6.75%).
| Period | West Pharmaceutical Services | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +8.01% | −3.17% | $1,080 |
| 6 months | +36.72% | +0.11% | $1,367 |
| Year to date | +50.71% | +8.34% | $1,507 |
| 1 year | +58.49% | +11.15% | $1,585 |
| 3 years | +22.02% | +64.30% | $1,220 |
| 5 years | −5.49% | +58.18% | $945 |
| 10 years | +435.70% | +239.10% | $5,357 |
Over the last 6 months it has done better than 75% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
West Pharmaceutical Services: technical analysis
West Pharmaceutical Services is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 12.1% below its highest close since January 2, 1990 ($471.34, December 30, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 63
- Between 30 and 70
- vs 200-session average
- +28.13%
Support and resistance
Price areas where West Pharmaceutical Services has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$414.12
- Support$384.19−7.23%4 touches, last on November 6, 2026
- Support$359.48−13.19%3 touches, last on October 8, 2026
- Support$331.43−19.97%2 touches, last on September 10, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.63
- Volatility (60 sessions, annualised)
- 22.9%
- Largest fall in the last year
- −18.77%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
West Pharmaceutical Services: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for West Pharmaceutical Services has been April: +3.27% on average, positive in 21 years out of 37. The weakest has been October: −0.24% on average, positive in 21 years out of 37. November, the current month, has been positive in 26 years out of 36 (+2.07% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.22% | −0.40% | 16 of 36 |
| February | −0.24% | +0.45% | 19 of 37 |
| March | +2.65% | +2.24% | 24 of 37 |
| April | +3.27% | +2.71% | 21 of 37 |
| May | +1.30% | +1.11% | 21 of 37 |
| June | +2.58% | +0.75% | 22 of 37 |
| July | +1.05% | +0.32% | 20 of 37 |
| August | +0.82% | +2.44% | 24 of 37 |
| September | +0.54% | +0.83% | 21 of 37 |
| October | −0.24% | +1.42% | 21 of 37 |
| November | +2.07% | +2.27% | 26 of 36 |
| December | +2.25% | +0.95% | 24 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
West Pharmaceutical Services and its competitors
Biologic, generic and pharmaceutical drug companies are the main customers for the packaging and delivery systems, while pharmaceutical, diagnostic and medical device companies order contract-manufactured devices. Sales reach the Americas, Europe, the Middle East, Africa and Asia Pacific through its sales force, contract sales agents and regional distributors. Product lines include stoppers and seals, syringe and cartridge parts, vials, self-injection devices and administration systems for reconstitution and mixing, along with inspection, sterilization and analytical lab services.
- Headquarters
- Exton, United States
- Employees
- 10,000
- Founded
- 1923
- Chief executive
- Michel Lagarde
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| West Pharmaceutical ServicesWST | $29.1B | 22.9% | 46.9 | +36.72% |
| ResMedRMD | $33.5B | 34.0% | 21.8 | +17.82% |
| MedlineMDLN | $42.57B | 5.0% | 40.2 | +4.12% |
| Becton, DickinsonBDX | $58.96B | 15.7% | 42.8 | +50.15% |
| SolventumSOLV | $15.07B | 5.9% | 99.6 | +15.89% |
| Baxter InternationalBAX | $13.41B | 7.6% | — | +48.90% |
Same industry or related industries, similar size. Compare West Pharmaceutical Services with its competitors · Full profile
More on West Pharmaceutical Services
- West Pharmaceutical Services revenue and financials
- West Pharmaceutical Services dividend and valuation
- West Pharmaceutical Services stock return
- West Pharmaceutical Services employees, headquarters and business
